Exhibit 10.1
AMENDED AND RESTATED
EXECUTIVE EMPLOYMENT AGREEMENT
for
JONATHAN G. DRACHMAN, MD
This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), andJonathan G. Drachman, MD (the “Executive” and, collectively with the Company, the “Parties”), is entered into as of April 15, 2020 (the “Effective Date”) and amends and restates that certain executive employment agreement entered into between the Parties as of August 5, 2019 (the “Prior Agreement”).
WHEREAS, Executive is the Chief Executive Officer of the Company; and
WHEREAS, the Parties wish to amend and restate the Prior Agreement as set forth herein.
NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:
1. Employment by the Company.
1.1Employment.This Agreement shall govern the terms of Executive’s employment with the Company, effective as of the Effective Date.
1.2Position. Executive shall continue to serve as the Company’s Chief Executive Officer. During the term of Executive’s employment with the Company, Executive will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company.
1.3Duties and Location. Executive shall perform such duties as are typically performed by a Chief Executive Officer. Executive will report to the Company’s Board of Directors. Executive’s primary office location shall be the Company’s office located in Seattle, Washington.
1.4Policies and Procedures. The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company’s general employment policies or practices, this Agreement shall control.
2. Compensation.
2.1Salary. For services to be rendered hereunder, Executive shall receive a base salary at the rate of Four Hundred and Twenty Five Thousand U.S. Dollars ($425,000) per year (such base salary, as may be increased (but not decreased) from time to time, the“Base Salary”), subject to standard payroll deductions and withholdings and payable in accordance with the Company’s regular payroll schedule.
2.2Bonus. Executive will be eligible for an annual discretionary bonus of up to 50% of Executive’s Base Salary (the“Annual Bonus”). Whether Executive receives an Annual Bonus for any given year, and the amount of any such Annual Bonus, will be determined by the Company’s Board of Directors (the“Board”) or the compensation committee thereof in its sole discretion based upon the Company’s and Executive’s achievement of objectives and milestones to be determined on an annual basis by the Board or the compensation committee thereof. Annual Bonuses are typically paid no later than March 15th of the year following the applicable bonus year. Executive will not be eligible for, and will not earn, any Annual Bonus (including a prorated bonus) if Executive’s employment terminates for any reason before any Annual Bonus is paid, except as otherwise expressly provided in Section 5.3 below.